NYSE: DNMRDanimer Scientific Inc Stock
$0.81-0.04 (-4.71%)
Updated Apr 24, 2024
DNMR Price
$0.81
Fair Value Price
N/A
Market Cap
$92.19M
52 Week Low
$0.60
52 Week High
$3.56
P/E
-0.53x
P/B
0.33x
P/S
2.23x
PEG
N/A
Dividend Yield
N/A
Revenue
$46.68M
Earnings
-$155.47M
Gross Margin
-57.7%
Operating Margin
-268.86%
Profit Margin
-333%
Debt to Equity
1.51
Operating Cash Flow
-$47M
Beta
1.9
Next Earnings
May 8, 2024
Ex-Dividend
N/A
Next Dividend
N/A
DNMR Overview
Live Oak Acquisition Corp. focuses to engage in a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or related business combination with one or more businesses. The company was formerly known as Foxhound Merger Partners, Inc. Live Oak Acquisition Corp. was founded in 2019 and is based in Great Falls, Virginia.
Zen Score
–
Industry Average (36)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how DNMR scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
DNMR is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
DNMR is good value based on its book value relative to its share price (0.33x), compared to the US Specialty Chemicals industry average (3.36x)
P/B vs Industry Valuation
DNMR is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more DNMR due diligence checks available for Premium users.
Be the first to know about important DNMR news, forecast changes, insider trades & much more!
DNMR News
Valuation
DNMR price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.53x
Industry
30.27x
Market
41.27x
DNMR price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.33x
Industry
3.36x
DNMR is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
DNMR's financial health
Profit margin
Revenue
$10.9M
Net Income
-$39.4M
Profit Margin
-360.3%
DNMR's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
DNMR's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$698.1M
Liabilities
$420.1M
Debt to equity
1.51
DNMR's short-term assets ($108.04M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
DNMR's long-term liabilities ($404.39M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
DNMR's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
DNMR's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$15.9M
Investing
-$2.0M
Financing
-$458.0k
DNMR's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
DNMR vs Specialty Chemical Stocks
Danimer Scientific Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.